在胰腺管道腺癌中,更有针对性的治疗趋势
Chiara Deiana1, Margherita Agostini1, Giovanni Brandi1,2
1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Expert review of anticancer therapy
|May 20, 2024
概括
胰腺管道腺癌 (PDAC) 仍然对向治疗有抗性. 本综述分析了针对各种目标的当前和未来试验,强调了用于改善患者存活率的组合治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 胰腺管腺癌 (PDAC) 对向疗法的显著耐药性,需要组合化疗方案.
- 尽管取得了进展,但由于癌症的复杂性,PDAC的有效向药物单一治疗仍然难以捉摸.
研究的目的:
- 审查PDAC中已确定的和新的治疗点的过去和正在进行的临床试验.
- 分析各种向药物的疗效和组合策略.
- 确定PDAC向治疗的有希望的未来方向.
主要方法:
- 对PDAC目标的临床试验数据的全面分析.
- 深入审查包括PARP,EGFR,HER2,KRAS通路,JAK/STAT,血管新生,新陈代谢,表观遗传学,克劳丁,P53和积分蛋白在内的目标.
- 对试验结果的评估,以评估治疗潜力.
主要成果:
- 许多目标正在接受调查,包括众所周知的和新兴的代理商.
- 组合疗法越来越被认为是克服PDAC耐药性的关键.
- 目前正在进行的试验正在探索各种治疗策略和组合.
结论:
- 针对PDAC的向治疗是复杂的,不太可能通过单一治疗来解决.
- 未来的研究应该专注于确定最佳组合治疗方法和有希望的新目标.
- 仔细选择目标和组合对于改善PDAC患者的整体存活率至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:29Chronic Pancreatitis II: Collaborative Care
84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
84